Skip header and navigation

3 records – page 1 of 1.

Bupropion (Zyban, sustained-release tablets): update.

https://arctichealth.org/en/permalink/ahliterature195667
Source
CMAJ. 2000 Jan 11;162(1):106-7, 110-1
Publication Type
Article
Date
Jan-11-2000

A retrospective survey of the use of bupropion slow release by members of the Canadian Armed Forces.

https://arctichealth.org/en/permalink/ahliterature186665
Source
Can J Clin Pharmacol. 2002;9(4):205-13
Publication Type
Article
Date
2002
Author
Régis Vaillancourt
Hieke Wagenaar
Cora Fisher
R D Conway
Joanne Plemel
Author Affiliation
Canadian Forces Health Services, Ottawa, Ontario, Canada. ab672@issc.debbs.ndhg.dnd.ca
Source
Can J Clin Pharmacol. 2002;9(4):205-13
Date
2002
Language
English
Publication Type
Article
Keywords
Adult
Bupropion - adverse effects - therapeutic use
Canada
Delayed-Action Preparations
Dopamine Uptake Inhibitors - adverse effects - therapeutic use
Female
Humans
Male
Military Personnel
Retrospective Studies
Smoking Cessation
Tobacco Use Disorder - drug therapy
Treatment Outcome
Abstract
Since the addition of bupropion slow release (Zyban, GlaxoSmithKline, Mississauga) to the Department of National Defence (DND) smoking cessation program (Butt Out), utilizing bupropion (Zyban) in combination with behaviour modification counselling, the Directorate of Medical policy has received several anecdotal reports from pharmacists and Canadian Forces members attributing significant side effects to the use of Zyban. As a result, the DND wished to assess the benefits versus the risks of using Zyban as part of the smoking cessation program. Subsequently, a retrospective review of the use of Zyban within the Canadian Forces over a one-year period was solicited to assess current policies.
Surveys were sent to Canadian Forces members receiving Zyban between September 1, 1998 and August 31, 1999. Members were questioned about smoking history and current status, perceived effectiveness of bupropion and both positive and negative experiences with the drug. Those reporting side effects and who had consented were contacted for an interview to obtain further details and information regarding the use of medical resources and effects on job performance. Members of the Canadian Forces visiting a doctor due to side effects were asked for permission to review their medical charts.
Zyban was dispensed to approximately 1171 members over the one-year period and 357 responded to the survey. The point prevalence smoking cessation rate was 47% at the time of the survey and ex-smokers had been smoke-free for a mean of 181 days. Approximately 91% of ex-smokers and 52% of smokers found Zyban helpful in quitting. Side effects were reported by 252 members and 160 interviews were completed. Forty-three interviewees had seen a doctor because of side effects. Sixteen of the 43 charts were audited. Fifty-two respondents stated that side effects affected their ability to do their primary job. Two individuals were hospitalized for a total of six days.
In light of the demonstrated effectiveness of Zyban and the overwhelming health benefits associated with smoking cessation, it is recommended that the current policies of funding for the DND smoking cessation program be left in place. The impact of Zyban's side effects on job performance and medical resources should be minimized through close monitoring and Zyban prescriptions should be dispensed in two-week quantities.
PubMed ID
12584579 View in PubMed
Less detail

Use of varenicline versus bupropion and risk of psychiatric adverse events.

https://arctichealth.org/en/permalink/ahliterature115990
Source
Addiction. 2013 Jul;108(7):1336-43
Publication Type
Article
Date
Jul-2013
Author
Björn Pasternak
Henrik Svanström
Anders Hviid
Author Affiliation
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark. bjp@ssi.dk
Source
Addiction. 2013 Jul;108(7):1336-43
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Adult
Benzazepines - adverse effects
Bupropion - adverse effects
Denmark
Dopamine Uptake Inhibitors - adverse effects
Female
Humans
Male
Mental Disorders - chemically induced
Middle Aged
Nicotinic Agonists - adverse effects
Proportional Hazards Models
Quinoxalines - adverse effects
Risk factors
Smoking - prevention & control
Smoking Cessation - methods
Treatment Outcome
Abstract
To investigate whether varenicline use was associated with increased risk of psychiatric adverse events, compared with bupropion, another drug used for smoking cessation.
We conducted a registry-based cohort study in Denmark, 2007-10, comparing new users of varenicline and bupropion in unmatched and 1 : 1 propensity score-matched analyses.
Using Cox regression, we estimated the hazard ratio (HR) of any psychiatric adverse event (emergency department visit or in-patient admission with a psychiatric diagnosis) within 30 days following treatment initiation. The unmatched and matched analyses correspond to conventional crude and fully adjusted analyses, respectively.
In unmatched analyses, there were 106 (0.18%) psychiatric adverse events among 59 790 varenicline users (rate 22 events per 1000 person-years), compared with 46 (0.26%) events among 17 936 bupropion users (rate 31 per 1000); the HR was 0.69 [95% confidence interval (CI): 0.49-0.98]. In propensity score-matched analyses, 39 (0.22%) events occurred among 17 935 varenicline users (rate 27 per 1000), compared with 46 (0.26%) events among 17 935 bupropion users (rate 31 per 1000); varenicline was not associated with increased risk of psychiatric adverse events (HR 0.85, 95% CI: 0.55-1.30). The overall rate of psychiatric adverse events was substantially higher among participants with a history of psychiatric disorder than in patients without such history; the risk associated with varenicline did not differ significantly by history of psychiatric disorder.
In Denmark, the risk of psychiatric adverse events diagnosed during an emergency department visit or in-patient admission was not significantly higher with varenicline use compared with bupropion.
PubMed ID
23445269 View in PubMed
Less detail